# Biology of Bladder Cancer (R01 Clinical Trial Optional)

Source: https://welltoldgrants.com/grants/par-25-129-biology-of-bladder-cancer-r01-clinical-trial-optional/  
Official notice: https://www.grants.gov/search-results-detail/357252

> National Institutes of Health offered grants to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. Applications closed on September 7, 2025.

| Field | Value |
|---|---|
| Opportunity number | PAR-25-129 |
| Agency | National Institutes of Health |
| Status | Forecast |
| Deadline | September 7, 2025 |
| Award ceiling | not stated |
| Award floor | not stated |
| Expected awards | not stated |
| Total funding | not stated |
| Cost sharing | not required |
| Assistance Listings | 93.393, 93.396 |

## Who can apply

- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and State controlled institutions of higher education
- Native American tribal governments (Federally recognized)
- Public housing authorities/Indian housing authorities
- Native American tribal organizations (other than Federally recognized tribal governments)
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- Private institutions of higher education
- For profit organizations other than small businesses
- Small businesses
- Others (see text field entitled "Additional Information on Eligibility" for clarification)

Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.

## What the grant funds

Through this Notice of Funding Opportunity (NOFO) solicits applications investigating the biology and underlying mechanisms of bladder cancer. Bladder cancer is a significant health problem both in the United States and globally. Because of the high incidence and frequent tumor recurrence, bladder cancer exacts an outsized medical burden. While recent progress has been made in the molecular profiling of bladder cancers and identification of mutated genes, relatively little is known regarding the molecular mechanisms driving initiation, progression, and malignancy of bladder cancer. Furthermore, our understanding of biological processes of the normal bladder at the molecular, cell and organ levels is limited. Fundamental knowledge of how molecular and cellular functions of the bladder are altered in cancer will aid our understanding of bladder cancer biology and interventions. Applications that involve multidisciplinary teams and use clinical specimens or investigate both normal and cancer processes are encouraged.

## Questions people ask

### Is PAR-25-129 still open?

No. It closed on September 7, 2025.

### Who can apply for Biology of Bladder Cancer (R01 Clinical Trial Optional)?

National Institutes of Health accepted applications from nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. The notice adds further conditions, so read its eligibility section.

### What is the deadline for Biology of Bladder Cancer (R01 Clinical Trial Optional)?

Closed September 7, 2025. Applications are no longer accepted; the program's newer notices are on this page when there are any.

### Who has been funded under PAR-25-129?

NIH RePORTER lists 2 projects funded under PAR-25-129 in fiscal 2026, at 2 institutions. The most were at Harvard Medical School, University of TX MD Anderson Can Ctr.

### Who has won Cancer Cause and Prevention Research grants before?

The largest recipients over five fiscal years were The Univeristy of Texas M.D. Anderson Cancer Center, Sloan-Kettering Institute for Cancer Research, The Trustees of Columbia University in the City of New York. The program made 2,517 awards worth $3.6 billion in that time.